Table 4.

Clinical variables recorded in the BMC2 data

	Features
Patient characteristics	Gender, body mass index, age
Cardiac status	Priority, staged PCI, salvage, ad hoc PCI, stable angina, cardiac arrest, unstable angina, high-risk non-cardiac surgery, atypical angina, patient turned down for coronary artery bypass graft by surgeon
PCI in the setting of myocardial infarction	Primary PCI, symptom to PCI time: 0–6 h, 6–12 h, 12–24 h and >24 h of symptoms, PCI of infarct related vessel, cardiogenic shock, recurrent ventricular tachycardia or ventricular fibrillation, post infarct angina, lytic therapy
Comorbidities	Current smoker, hypertension, insulin dependent diabetes, non-insulin-dependent diabetes, congestive heart failure, peripheral vascular disease, renal failure requiring dialysis, significant valve disease, current or recent gastrointestinal bleed, chronic obstructive pulmonary disorder, cerebrovascular disease, atrial fibrillation, history of cardiac arrest, previous myocardial infarction, previous PCI
Pre-procedure laboratory results	Creatinine, hemoglobin
Contraindications	Aspirin, angiotensin-converting enzyme inhibitors, β-blockers, cholesterol-lowering agents, clopidogrel
Pre-procedure therapy	Aspirin, intravenous heparin, low molecular weight heparin, bivalirudin, angiotensin-converting enzyme inhibitors, β-blockers, calcium antagonists, diuretics, coumadin, clopidogrel, thienopyridine, intra-aortic balloon pump, intubation
Cardiac anatomy and function	Left main artery stenosis, ejection fraction, no of diseased vessels, left ventricular end-diastolic pressure, graft lesion, grafts with >70% stenosis, ostial lesion, moderate to heavy calcification, thrombus, and chronic total occlusion

BMC2, Blue Cross Blue Shield of Michigan Cardiovascular Consortium; PCI, percutaneous coronary intervention.